Royal Philips NV announced a 4% increase in comparable sales for the first quarter. The company's headquarters in Amsterdam saw European sales rise on both a nominal and comparable basis. First-quarter nominal sales declined to 3.91 billion euros from 4.1 billion euros in the same period last year. Despite the drop in nominal revenue, the medical technology firm achieved particularly strong business growth in Western Europe. The Dutch company reported revenue of 3.91 billion euros (equivalent to 4.57 billion U.S. dollars), slightly surpassing analyst expectations of 3.88 billion euros. Meanwhile, comparable sales grew by 4% year-over-year. Royal Philips NV attributed this growth to a broad-based recovery in North American and European markets, as well as strong performance in its Personal Health division. Sales in Europe increased on both a nominal and comparable basis. Net profit for the first quarter of 2026 was 151 million euros, significantly higher than the 76 million euros recorded in the prior-year period and well above market expectations of 66 million euros. Full-Year Outlook: Royal Philips NV expects its full-year adjusted EBITA margin to be in the range of 12.5% to 13.0%. The company anticipates full-year comparable sales growth of 3% to 4.5%.